ANNAPOLIS, Md. & NEW YORK--(BUSINESS WIRE)--March 14, 2006--PharmAthene, Inc. and SIGA Technologies, Inc. (NASDAQ: SIGA) announced today that they have entered into a term sheet providing for the merger of PharmAthene and SIGA. The combined company, which intends to operate under the name PharmAthene, features a substantial portfolio of procurement-stage biodefense products targeting anthrax, smallpox and chemical nerve agents, as well as a robust pipeline of therapeutic and prophylactic drug candidates targeting Category A biowarfare agents and emerging infectious diseases.
